Immunoassay for F1.2 prothrombin fragment

Details Immunoassay for F1.2 prothrombin fragment Immunoassay for F1.2 prothrombin fragment

1988-02-03

2003-04-01

Duffy, Patricia A. (Department: 1645)

Chemistry: analytical and immunological testing

Involving an insoluble carrier for immobilizing immunochemicals

C435S007400, C435S007940, C436S547000, C436S548000, C530S387900

Reexamination Certificate

active

06541275

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to chemically synthesized immunogens which generate antibodies specific for the activation peptide from prothrombin, F1.2. In another aspect, it relates to methods for detecting the presence and/or concentration of F1.2 in plasma.
Many proteins are synthesized in vivo as inactive precursors, or zymogens, which are subsequently converted to their active forms by limited proteolysis. This process of zymogen activation is a rate-limiting step in a variety of physiological processes which include blood coagulation. Blood coagulation proteins are “activated” by highly specific, limited peptide bond cleavage, which generate new carboxy and amino termini. The amino acid sequence within these termini is highly specific for a particular coagulation protein. These termini which are often located at the surface of the protein, show a relatively high conformational flexibility and are frequently good antigenic determinants.
Prothrombin is one of a series of proteins that participate in the blood clotting mechanism. Thrombin has many functions including catalyzing the conversion of fibrinogen to fibrin, and thus preventing the loss of blood from the vascular system of vertebrates. Prothrombin is proteolytically cleaved to form its active state thrombin; in this conversion the polypeptide fragment F1.2 is formed.
The detection of prothrombin activation products within whole blood or plasma has been attempted using immunological methods, but has been impaired because of the cross-reactions between the activation products and the parent molecule. Studies on radioimmunologic techniques for F1.2 in human plasma, have shown that there is significant cross-reactivity between F1.2 and related proteins such as F1, prothrombin and prethrombin-2. Cross-reactivities between the activation product and prothrombin, thus preclude the quantitation of this fragment in whole blood. In addition, the concentration of prothrombin is exceedingly high compared with the minute quantities of activation fragment that is expected to be formed in vivo.
The isolation of specific antibody population directed against cleavage fragments has allowed for the demonstration of small amounts of F1.2 in normal human plasma, even in the presence of normal prothrombin levels. Lau et al.,
The Isolation and Characterization of Specific Antibody Population Directed Against the Prothrombin Activation Fragments F
2
and F
1+2, 254 J. Bio. Chem. 8751 (1979). Additionally, Prothrombin catabolism has also been studied by screening urine for prothrombin derivatives. Bezeaud et al.,
Identification of Prothrombin Derivatives in Human Urine,
13 Thrombin Res. 551 (1978). Further studies by this group showed that in urine, where prothrombin is absent, it was possible to accurately quantitate F1 and F2 fragments. Bezeaud et al,
Quantitation of Prothrombin Activiation Products in Human Urine,
58 Brit. J. Haemat. 597 (1984).
SUMMARY OF THE PRESENT INVENTION
According to the present invention, highly specific—low affinity antibodies are generated which allow for the assay of F1.2 in bodily fluids that also contain prothrombin, or other plasma proteins. The antibodies are made using synthetic polypeptides which mimic the carboxy terminus of F1.2. The synthetic polypeptide of this invention elicited antibodies specific for F1.2, but which do not bind to intact prothrombin or other plasma proteins. This specificity is of particular importance in measuring F1.2 in plasma since prothrombin is normally present in a 1000-fold molar excess over F1.2.
Many different peptides were synthesized. The specific synthetic polypeptide used to raise antibodies with the highest specificity for F1.2 was found to have the following amino acid sequence: [CYS-GLY]-ASP-ARG-ALA-ILE-GLU-GLY-ARG-OH. Glycine and cysteine residues were added to permit convenient attachment of the synthetic polypeptide to a carrier protein. These additional amino acids (CYS-GLY), however, are not critical to this invention. This polypeptide-protein conjugate was used to elicit an immune response in laboratory animals.


REFERENCES:
patent: 4287180 (1981-09-01), Thomas et al.
patent: 4289498 (1981-09-01), Baughman et al.
patent: 4334018 (1982-06-01), Kirchhof
patent: 4357321 (1982-11-01), Thomas et al.
patent: 4459288 (1984-07-01), Thomas et al.
patent: 4465623 (1984-08-01), Chanas et al.
patent: 4663164 (1987-05-01), Thomas et al.
patent: 4668621 (1987-05-01), Doellgast
patent: 0151239 (1985-08-01), None
patent: 88113124.7 (1988-08-01), None
patent: 0303983 (1989-02-01), None
Bidart et al. “Identification of Epitopes Associated With HCG and the B HCG Carboxyl Terminus by Monoclonal Antibodies Produced Against a Synthetic Peptide” J. Immunology vol. 134 No. 1, Jan. 1985 pp. 457-464.*
H. Lau et al., The Isolation and Characterization of a Specific Antibody Population Directed Against the Prothrombin Activation Fragments F2 and F1&2, 234 J. Biological Chemistry 8751 (1979).
G. Walter, “Antibodies Specific for the Carboxy-and amino-terminal Regions of Simian Virus 40 Large Tumor Antigen,” 77 Proc. Nat'l Acad. Sci. 5197 (1980).
J. Teitel et al., “Studies of Prothrombin Activation Pathway Utilizing Radioimmunoassays for F2/F1&2 Fragment and Thrombin-Antithrombin Complex,” 59 Blood 1086 (1982).
G. Walter et al., “Cross-Reactivity of Antibodies Against Synthetic Peptides,” 19 J. Cellular Biochem. 119 (1982).
K. Hui et al., “Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin but not Fibrinogen, ” Dec. 9, 1983.
Niman et al., “Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune rejection,” 80 Proc. Nat'l Acad. Sci. 4949 (1983).
Pacella et al., “Induction of Fibrin-Specific Antibodies by Immunization with Synthetic Peptides that Correspond to Amino Termini of Thrombin Cleavage Sites, ” Cellular Immuno 521 (1983).
A. Bezeaud, “Quantitation of Prothrombin Activation Products in Human Urine” 58 British J. Haematology 597 (1984).
Lerner, “Antibodies of Predetermined Specificity in Biology and Medicine,” Advance in Immunology v. 36 (1984).
Friquet et al., “Measurements of True Affinity Constant in Solution of Antigen-Antibody Complexes by Enzyme-Linked Immunosorbent Assay,” J. Immuno Methods 305 (1985).
A. Moriarty et al., “Antibodies to Peptides Detect New Hepatitis B Antigen: Serological Correlation with Hepatocellular Carcinoma,”227 Science 429 (1985).
Muller-Berghaus et al., “Detection of Fibrin in Plasma by a Monoclonal Antibody Against the Amino-terminus of the Alpha-chain of Fibrin,” 45 Scand. J. Clin. Inves. 145 (1985).
Scheefers-Borchet et al., “Discrimination between Fibrin and Fibrinogen by a Monoclonal Antibody Against a Synthetic Peptide,” 82 Proc. Natl. Acad. Sci. 7091 (1985).
Abstract, “Detection of Prothrombin Activation Fragments F2/F1&2 by an Antibody Against a Synthetic Peptide,” German Congress for Thrombosis, Frankfort, Feb. 24-27, 1988.

Affiliated with

Also associated with

Rating

Immunoassay for F1.2 prothrombin fragment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoassay for F1.2 prothrombin fragment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoassay for F1.2 prothrombin fragment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3112351